Efficacy and Safety of a 5-Day Regimen of Azacitidine for Patients with High-Risk Myelodysplastic Syndromes

被引：0
|
作者：
Fujimaki, Katsumichi [1 ]
Miyashita, Kazuho [1 ]
Kawasaki, Rika [1 ]
Tomita, Naoto [2 ]
Ishigatsubo, Yoshiaki [2 ]
机构：
[1] Fujisawa City Hosp, Fujisawa, Kanagawa, Japan
[2] Yokohama City Univ, Grad Sch Med, Yokohama, Kanagawa 232, Japan
来源：
BLOOD | 2014年 / 124卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Efficacy and safety of a 5-day regimen of azacitidine for patients with high-risk myelodysplastic syndromes
    Fujimaki, Katsumichi
    Miyashita, Kazuho
    Kawasaki, Rika
    Tomita, Naoto
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2016, 97 (03) : 228 - 231
  • [2] Safety and efficacy of azacitidine in elderly patients with intermediate to high-risk myelodysplastic syndromes
    Navada, Shyamala C.
    Silverman, Lewis R.
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2017, 8 (01) : 21 - 27
  • [3] EFFICACY AND TOLERABILITY OF 5-DAY AZACYTIDINE DOSE INTENSIFIED REGIMEN IN HIGHER RISK MYELODYSPLASTIC SYNDROMES
    Pierdomenico, F.
    Parreira, A.
    Almeida, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 563 - 563
  • [4] A phase II study of 5-day intravenous azacitidine in patients with myelodysplastic syndromes
    Martin, Mike G.
    Walgren, Richard A.
    Procknow, Elizabeth
    Uy, Geoffrey L.
    Stockerl-Goldstein, Keith
    Cashen, Amanda F.
    Westervelt, Peter
    Abboud, Camille N.
    Kreisel, Frederieke
    Augustin, Kristan
    DiPersio, John F.
    Vij, Ravi
    AMERICAN JOURNAL OF HEMATOLOGY, 2009, 84 (09) : 560 - 564
  • [5] Efficacy and safety of venetoclax plus azacitidine for patients with treatment-naive high-risk myelodysplastic syndromes
    Garcia, Jacqueline S.
    Platzbecker, Uwe
    Odenike, Olatoyosi
    Fleming, Shaun
    Fong, Chun Yew
    Borate, Uma
    Jacoby, Meagan A.
    Nowak, Daniel
    Baer, Maria R.
    Peterlin, Pierre
    Chyla, Brenda
    Wang, Huipei
    Ku, Grace
    Hoffman, David
    Potluri, Jalaja
    Garcia-Manero, Guillermo
    BLOOD, 2025, 145 (11) : 1126 - 1135
  • [6] Survival and efficacy of decitabine in myelodysplastic syndromes (MDS), analysis of the 5-day IV dosing regimen
    Kantarjian, Hagop
    Garcia-Manero, Guillermo
    O'Brien, Susan
    Estrov, Zeev
    Ravandi, Farhad
    Cortes, Jorge
    Shan, Jianqin
    Davisson, Jan
    Issa, Jean-Pierre
    BLOOD, 2007, 110 (11) : 42A - 42A
  • [7] AZACITIDINE: AN ALTERNATIVE TREATMENT REGIMEN FOR ELDERLY HIGH-RISK MYELODYSPLASTIC PATIENTS
    Ramakrishna, R.
    Alexander, W.
    Sarathy, K.
    HAEMATOLOGICA, 2013, 98 : 583 - 584
  • [8] Safety and efficacy of azacitidine in myelodysplastic syndromes
    Vigil, Carlos E.
    Martin-Santos, Taida
    Garcia-Manero, Guillermo
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2010, 4 : 221 - 229
  • [9] Azacitidine delivers dramatic results in patients with high-risk myelodysplastic syndromes
    不详
    EXPERT REVIEW OF HEMATOLOGY, 2009, 2 (02) : 120 - 120
  • [10] Azacitidine delivers dramatic results in patients with high-risk myelodysplastic syndromes
    Fenaux, P.
    Mufti, G. J.
    Hellstrom-Lindberg, E.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2009, 9 (04) : 395 - 395
12345